Clinical Trials Logo
  1. Home
  2. Liver Cancer
  3. NCT05681234
  4. Details
NCT05681234 Clinical Trial

Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Liver Carcinoma Clinical Trial

Official title:
Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05681234
Other study ID # LS2021058
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 24, 2022
Est. completion date December 20, 2022

Study information
Verified date December 2022
Source Affiliated Hospital of Jiangnan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single arm study to evaluate the safety and biodistribution of 18F-labeled RD2 PET/CT Imaging in patients with small liver carcinoma.

Recruitment information / eligibility
Status Completed
Enrollment 30
Est. completion date December 20, 2022
Est. primary completion date November 2, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with highly suspected tumor; 2. Patients underwent PET/CT examination within 1 week; 3. Patients voluntarily signed informed consent; 4. Over 18 years old, male or female. Exclusion Criteria: 1. Pregnant women; 2. Lactating women; 3. Patients with impaired renal function.

Study Design

Related Conditions & MeSH terms

Intervention

Radiation:
• 18F-RD2
Patients will receive 5-10 mCi 18F-RD2

Locations
Country Name City State
China Affiliated Hospital of Jiangnan University Wuxi Jiangsu

Sponsors (1)
Lead Sponsor Collaborator
Affiliated Hospital of Jiangnan University

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluation of tissue distribution of 18F-RD2 Biodistribution of 18F-RD2 evaluated by radioactive uptake values (standardized uptake values, SUVs) in various organs during repeated 18F-RD2 scans will be reported. 2 hours
See also
  Status Clinical Trial Phase
Terminated NCT01020812 - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04443322 - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) N/A
Completed NCT02305459 - CIRSE Registry for SIR-Spheres Therapy
Terminated NCT00791544 - Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma Phase 1/Phase 2
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Completed NCT02424955 - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation N/A
Completed NCT03775863 - AFP Model and Liver Transplantation.
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Recruiting NCT06144385 - A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma Phase 1
Completed NCT01717729 - Hepatocellular Carcinoma Treated With Iodine-125 Implantation Phase 3
Completed NCT03178409 - Combined HCC-MFCCC N/A
Suspended NCT04955808 - Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Recruiting NCT01380392 - The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma N/A
Withdrawn NCT01744639 - Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation N/A
Completed NCT01482442 - SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma Phase 3
Active, not recruiting NCT01272557 - Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial Phase 2
Completed NCT00328770 - De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Phase 2/Phase 3
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Active, not recruiting NCT02465060 - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Phase 2
Recruiting NCT04288323 - Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis Phase 4